* Biocon said in a statement that the settlement gives it the “earliest licensed launch dates” for a Perjeta biosimilar, allowing the company to launch its Pebrilzo in the first quarter of 2027 in the UK and European Union, and the third quarter of 2028 in the United States
Also Read: Biocon founder Kiran Mazumdar Shaw says India must shift pharma industry from generics to innovation-led growth
* The release said that other terms of the agreement are confidential
* Biosimilars are versions of biologic drugs that are comparable to generics of traditional pharmaceuticals. Unlike traditional drugs, complex biologic drugs are made from living cells and cannot be copied exactly
* Genentech’s biologic Perjeta was Switzerland-based Roche’s sixth-best-selling drug last year, earning it nearly CHF 2.97 billion ($3.67 billion) in revenue worldwide, according to a company report
Also Read: Biocon clears path for cancer drug launch* Genentech sued Biocon in New Jersey earlier this year, alleging Biocon’s biosimilar would infringe its patents
* The court dismissed the lawsuit on Wednesday at Genentech’s request
* Biocon did not respond to Genentech’s allegations in court
